Newell Brands Initiates Outlook - Quick Facts

Newell Brands (NWL) said, for the first quarter, the company projects: normalized EPS of $0.12 to $0.14; high single digit core sales growth; and net sales of $2.04 billion to $2.08 billion.

For full year 2021, the company expects: normalized EPS in a range of $1.55 to $1.65; low single digit core sales growth; and net sales of $9.5 billion to $9.7 billion.

Fourth quarter normalized earnings per share were $0.56 compared to $0.42, prior year. Core sales grew 4.9 percent. Net sales were $2.7 billion, an increase of 2.5 percent.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
IBSA Pharma Inc. is recalling 27 lots of TIROSINT-SOL (levothyroxine sodium) Oral Solution to the consumer level due to subpotency, the U.S. Food and Drug Administration said. TIROSINT-SOL is indicated for Hypothyroidism and Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression. Meanwhile, the recall does not apply to TIROSINT (levothyroxine sodium) capsules. The U.S. Food and Drug Administration approved GlaxoSmithKline LLC's Jesduvroq tablets (daprodustat) for anemia caused by chronic kidney disease or CKD for adults who have been receiving dialysis for at least four months. It is the first oral treatment for anemia, i.e., decreased number of red blood cells, in the given indication that has received FDA approval. German banking major Deutsche Bank AG reported Thursday a significantly higher profit in its fourth quarter and fiscal 2022, mainly reflecting a tax benefit in the U.S, despite weakness in Investment Bank and asset management revenues. The company said it recorded its highest annual profit, both before and after tax, since 2007. However, Deutsche Bank shares were losing around 4 percent...
Follow RTT